Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults

Human Vaccines

Volumn 7, Issue 9, 2011, Pages 919-928

  Musher, Daniel M ^a,b   Manoff, Susan B ^c   McFetridge, Richard D ^c   Liss, Charles ^c   Marchese, Rocio D ^c   Raab, Jennifer ^d   Rueda, Adriana M ^a,b   Walker, Monica L ^c   Hoover, Patricia A ^c  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d PPD Vaccine and Biologics   (United States)

Author keywords

Antibody persistence; Immunogenicity; Pneumococcal polysaccharide vaccine; Pneumovax 23; Revaccination

Indexed keywords

IMMUNOGLOBULIN G; PNEUMOCOCCUS VACCINE;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MALE; MYALGIA; OUTCOME ASSESSMENT; PNEUMOCOCCAL INFECTION; REVACCINATION; SEROTYPE; SYSTEMIC DISEASE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; TIME FACTORS;

EID: 80053500120     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.9.15996     Document Type: Article

References (32)

1. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997; 46:1-24.
2. Jackson LA, Neuzil KM. Pneumococcal polysaccharide vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Eds. Vaccines. Saunders Elsevier 2008; 5:569-604.
3. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008; 2008:422 DOI:10.1002/14651858.CD000422.pub2; PMID:18253977.
4. Musher DM, Manoff SB, Liss C, McFetridge RD, Marchese RD, Painter CA, et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis 2010; 201:516-24; PMID:20092407; DOI:10.1086/649839.
5. Manoff S, Liss C, Caulfield MJ, Marchese R, Silber J, Boslego J, et al. Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults ≥65 years of age. J Infect Dis 2010; 201:525-33; PMID:20088694; DOI:10.1086/651131.
6. Hammit LL, Bulkow LR, Singleton RJ, Nuorti JP, Hummel KB, Miernyk KM, et al. Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: No evidence of hyporesponsiveness. Vaccine 2011; 29:2287-95; PMID:21255685; DOI:10.1016/j.vaccine. 2011.01.029.
7. Jackson LA, Benson P, Sneller VP, Butler JC, Thompson RS, Chen RT, et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 1999; 281:243-8; PMID:9918479; DOI:10.1001/jama.281.3.243.
8. Walker FJ, Singleton RJ, Bulkow LR, Strikas RA, Butler JC. Reactions after 3 or more doses of pneumococcal polysaccharide vaccine in adults in Alaska. Clin Infect Dis 2005; 40:1730-5; PMID:15909258; DOI:10.1086/430305.
9. Jackson LA, Nelson JC, Whitney CG, Neuzil KM, Benson P, Malais D, et al. Assessment of the safety of a third dose of pneumococcal polysaccharide vaccine in the Vaccine Safety Datalink population. Vaccine 2006; 24:151-6; PMID:16122845; DOI:10.1016/j.vaccine.2005.07.066.
10. Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325:1453-60; PMID:1944423; DOI:10.1056/NEJM199111213252101.
11. Musher DM. Streptococcus pneumoniae. In: Mandell GL, et al. Eds. Mandell, Douglas and Bennett's Principles & Practice of Infectious Diseases, Churchill Livingstone, Philadelphia 2009; 7:2623-42.
12. O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharides vaccines: is hyporesponsiveness an issue? Lancet Infect Dis 2007; 7:597-606; PMID:17714673; DOI:10.1016/S1473-3099(07)70210-4.
13. Finland M. The serum treatment of lobar pneumonia. N Engl J Med 1930; 202:1244-7 DOI:10.1056/NEJM193006262022605.
14. Finland M, Sutliff WD. The specific serum treatment of pneumococcus type II pneumonia. JAMA 1933; 100:560-6.
15. Cecil RL. Effects of very early serum treatment in pneumococcus type I pneumonia. JAMA 1937; 108:689-92.
16. Casadevall A, Scharff MD. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother 1994; 38:1695-702; PMID:7985997.
17. Heidelberger M, Dilapi MM, Siegel M, Walter AW. Persistence of antibodies in human subjects injected with pneumococcal polysaccharides. J Immunol 1950; 65:535-41; PMID:14794919.
18. Mufson MA, Hughey DF, Turner CE, Schiffman G. Revaccination with pneumococcal vaccine of elderly persons 6 years after primary vaccination. Vaccine 1991; 9:403-7; PMID:1887670; DOI:10.1016/0264-410X(91)90126-Q.
19. Davidson M, Bulkow LR, Grabman J, Parkinson AJ, Chamblee C, Williams WW, et al. Immunogenicity of pneumococcal revaccination in patients with chronic disease. Arch Intern Med 1994; 154:2209-14; PMID:7944842; DOI:10.1001/archinte. 154.19.2209.
20. Musher DM, Groover JE, Rowland JM, Watson DA, Struewing JB, Baughn RE, et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence and response to revaccination. Clin Infect Dis 1993; 17:66-73; PMID:8353248; DOI:10.1093/clinids/17.1.66.
21. Konradsen HB. Quantity and avidity of pneumococcal antibodies before and up to five years after pneumococcal vaccination of elderly persons [With Published Erratum]. Clin Infect Dis 1995; 21:616-20; PMID:8527553; DOI:10.1093/clinids/21.3.616.
22. Sankilampi U, Honkanen PO, Bloigu A, Leinonen M. Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly. J Infect Dis 1997; 176:1100-4; PMID:9333177; DOI:10.1086/516521.
23. Ridda I, MacIntyre CR, Lindley R, Gao Z, Sullivan JS, Yuan FF, et al. Immunological responses to pneumococcal vaccine in frail older people. Vaccine 2009; 27:1628-36; PMID:19100304; DOI:10.1016/j.vaccine.2008.11.098.
24. Törling J, Hedlund J, Konradsen HB, Örtqvist Å. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia. Vaccine 2003; 22:96-103; PMID:14604576; DOI:10.1016/S0264-410X(03)00521-8.
25. Musher DM, Rueda AM, Nahm MH, Graviss EA, Rodriguez-Barradas MC. Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. J Infect Dis 2008; 198:1019-27; PMID:18710324; DOI:10.1086/591629.
26. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006; 24:1159-69; PMID:16213065; DOI:10.1016/j.vaccine.2005.08.105.
27. Fisman DN, Agrawal D, Leder K. The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis. Clin Infect Dis 2002; 35:1368-75; PMID:12439800; DOI:10.1086/344271.
28. Landgren O, Björkholm M, Konradsen HB, Söderqvist M, Nilsson B, Gustavsson A, et al. A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkin's lymphoma. J Intern Med 2004; 255:664-73; PMID:15147530; DOI:10.1111/j.1365-2796.2004.01312.x.
29. Honkanen PO, Keistinen T, Kivela SL. Reactions following administration of influenza vaccine alone or with pneumococcal vaccine to the elderly. Arch Intern Med 1996; 156:205-8; PMID:8546555; DOI:10.1001/archinte.156.2.205.
30. D'Alessandro D, Rossini A, Fara GM, Ciriminna S. Reactogenicity trends by age to influenza and pneumococcal vaccines. J Am Geriatr Soc 2005; 53:910-1; PMID:15877578; DOI:10.1111/j.1532-5415.2005.53278-2.x.
31. Sankilampi U, Honkanen PO, Pyhala R, Leinonen M. Associations of prevaccination antibody levels with adverse reactions to pneumococcal and influenza vaccines administered simultaneously in the elderly. Vaccine 1997; 15:1133-7; PMID:9269058; DOI:10.1016/S0264-410X(96)00317-9.
32. Marchese RD, Jain NT, Antonello J, Mallette L, Butterfield-Gerson KL, Raab J, et al. Enzyme-linked immunosorbent assay for measuring antibodies to pneumococcal polysaccharides for the PNEUMOVAX 23 vaccine: assay operating characteristics and correlation to the WHO International Assay. Clin Vaccine Immunol 2006; 13:905-12; PMID:16893991; DOI:10.1128/CVI.00014-06.